Please login to the form below

Not currently logged in
Email:
Password:

filgotinib

This page shows the latest filgotinib news and features for those working in and with pharma, biotech and healthcare.

Gilead’s Jyseleca is given a NICE recommendation for rheumatoid arthritis

Gilead’s Jyseleca is given a NICE recommendation for rheumatoid arthritis

Jyseleca (filgotinib) is an oral JAK inhibitor that can be administered as a monotherapy or used alongside another another common RA medicine called methotrexate. ... The FDA has expressed concerns regarding the overall benefit/risk profile of the

Latest news

More from news
Approximately 3 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Setting up for success in a post-Brexit, post-pandemic Britain Setting up for success in a post-Brexit, post-pandemic Britain

    Recently, Galapagos and Gilead Sciences received a positive NICE recommendation for Jyseleca (filgotinib) for use on the NHS which, for the first time, will support access to an advanced therapy for

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Sales are projected at $1.589bn in 2024. 5. Filgotinib from Gilead/Galapagos is an oral JAK1 inhibitor in regulatory review in the US, EU and Japan for rheumatoid arthritis Overactivation ... If approved, filgotinib will be a late entrant into a very

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    filgotinib for rheumatoid arthritis. ... and filgotinib’s anticipated launch this year meets expectations in the increasingly competitive market for JAK inhibitors.

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    is its experimental JAK1 inhibitor filgotinib for rheumatoid arthritis. ... This will include broader commercial rights in Europe for filgotinib, due to be filed later this year, setting up a 2020 launch.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest ... Likewise, upadacitinib will face competition

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...